SINGAPORE INSTITUTE OF ADVANCED MEDICINE HOLDINGS LTD.

(Incorporated in the Republic of Singapore on 24 November 2011)
(Company Registration Number: 201134046D)

UPDATE IN RELATION TO THE PROPOSED CONVERSION OF SHAREHOLDER'S LOANS FROM ESPEETEX SDN. BHD. INTO NEW SHARES

Unless otherwise defined or the context otherwise requires, all capitalised terms used herein bear the same meanings as in the Announcements (as defined below).

The Board of Directors (the "**Board**") of Singapore Institute of Advanced Medicine Holdings Ltd. (the "**Company**", together with its subsidiaries, collectively, the "**Group**") refers to the Company's announcements dated 30 October 2025, 13 February 2026, 22 April 2026 and 30 October 2026 (collectively, the "**Announcements**") in relation to, *inter alia*, the proposed Espeetex Loan Conversion.

Further to the Announcements, the Board wishes to update that, in view that the parties will be unable to fulfil the conditions precedent under the Espeetex Loan Conversion Deed by the long stop date of 13 November 2026, the Company and Espeetex have mutually agreed not to proceed with the proposed Espeetex Loan Conversion. Accordingly, the Company and Espeetex have on 7 November 2026 terminated the Espeetex Loan Conversion Deed by way of a letter agreement. Save for the provisions expressed to survive termination, the parties have been released and discharged from their respective obligations thereunder.

For completeness of disclosure, the Company and Espeetex have concurrently entered into a letter agreement to extend the maturity date of the shareholder loans owing by the Company to Espeetex, amounting to an aggregate principal amount of S$22.0 million, to 31 December 2027 (the "**Extension**"). The Extension is an interested person transaction, of which amount-at-risk aggregated with amount-at-risk of other transactions entered into with the same interested person during the current financial year is below 3% of the Group's latest audited net tangible asset value.

Following the termination of the Espeetex Loan Conversion Deed, the Company will be withdrawing its application to the Securities Industry Council for the Whitewash Waiver in connection with the proposed Espeetex Loan Conversion.

The termination of the Espeetex Loan Conversion Deed is not expected to have any material impact on the net tangible assets per share or earnings per share of the Company for the financial year ending 30 June 2027.

BY ORDER OF THE BOARD

Dr Djeng Shih Kien
Executive Director and Chief Executive Officer
7 November 2026

This announcement has been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. (the "**Sponsor**"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "**Exchange**") and the Exchange assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Ms Ng Shi Qing, 16 Collyer Quay, #10-00 Collyer Quay Centre, Singapore 049318, sponsorship@ppcf.com.sg.